JP2022514381A5 - - Google Patents
Info
- Publication number
- JP2022514381A5 JP2022514381A5 JP2021535670A JP2021535670A JP2022514381A5 JP 2022514381 A5 JP2022514381 A5 JP 2022514381A5 JP 2021535670 A JP2021535670 A JP 2021535670A JP 2021535670 A JP2021535670 A JP 2021535670A JP 2022514381 A5 JP2022514381 A5 JP 2022514381A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- administration
- crazakizumab
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783136P | 2018-12-20 | 2018-12-20 | |
| US62/783,136 | 2018-12-20 | ||
| US201962855993P | 2019-06-01 | 2019-06-01 | |
| US62/855,993 | 2019-06-01 | ||
| PCT/US2019/068103 WO2020132600A1 (en) | 2018-12-20 | 2019-12-20 | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514381A JP2022514381A (ja) | 2022-02-10 |
| JP2022514381A5 true JP2022514381A5 (https=) | 2022-12-19 |
Family
ID=71101983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535670A Pending JP2022514381A (ja) | 2018-12-20 | 2019-12-20 | 臓器移植の慢性抗体介在性拒絶反応の処置でのクラザキズマブ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220073605A1 (https=) |
| EP (1) | EP3897718A4 (https=) |
| JP (1) | JP2022514381A (https=) |
| KR (1) | KR20210106521A (https=) |
| CN (1) | CN113194996B (https=) |
| AU (1) | AU2019404553A1 (https=) |
| BR (1) | BR112021010615A2 (https=) |
| CA (1) | CA3121934A1 (https=) |
| WO (1) | WO2020132600A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| EP4025596A4 (en) * | 2019-09-04 | 2023-09-20 | Cedars-Sinai Medical Center | Use of calcineurin inhibitor free ctla4-ig + anti-il6/il6r for long term immunosuppression in solid organ transplant recipients |
| WO2025122579A1 (en) * | 2023-12-04 | 2025-06-12 | Cedars-Sinai Medical Center | Cadherin 6 expression status in determination of renal fibrosis and related uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| EP2834368A2 (en) * | 2012-04-04 | 2015-02-11 | Assistance Publique - Hopitaux De Paris | Endothelial cells activation biomarkers characterizing antibody mediated rejection and uses thereof |
| WO2014122143A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| EP4162947A1 (en) * | 2013-11-22 | 2023-04-12 | Takeda Pharmaceutical Company Limited | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| US11065319B2 (en) * | 2014-02-04 | 2021-07-20 | 3Dt Holdings, Llc | Methods for diagnosing and reducing incidences of cardiac allograft rejection |
| US20170022280A1 (en) * | 2015-07-24 | 2017-01-26 | Cedars-Sinai Medical Center | Method for treating antibody-mediated rejection post-transplantation |
| BR112020013531A2 (pt) * | 2018-01-04 | 2020-12-08 | Vitaeris, Inc. | Uso de anticorpo anti-il-6, por exemplo, clazakizumab para dessensibilização de receptores de transplante de órgãos sólidos e/ou para prevenir, estabilizar ou reduzir rejeição mediada por anticorpos (abmr) |
| EP3877412A4 (en) * | 2018-11-08 | 2022-08-10 | Cedars-Sinai Medical Center | USE OF CLAZAKIZUMAB TO DESENSITIZE AND ENHANCE KIDNEY TRANSPLANTATION IN HLA-SENSITIVE PATIENTS |
-
2019
- 2019-12-20 KR KR1020217022866A patent/KR20210106521A/ko active Pending
- 2019-12-20 CN CN201980084166.7A patent/CN113194996B/zh active Active
- 2019-12-20 BR BR112021010615A patent/BR112021010615A2/pt unknown
- 2019-12-20 AU AU2019404553A patent/AU2019404553A1/en active Pending
- 2019-12-20 US US17/415,993 patent/US20220073605A1/en not_active Abandoned
- 2019-12-20 JP JP2021535670A patent/JP2022514381A/ja active Pending
- 2019-12-20 CA CA3121934A patent/CA3121934A1/en active Pending
- 2019-12-20 EP EP19900083.7A patent/EP3897718A4/en active Pending
- 2019-12-20 WO PCT/US2019/068103 patent/WO2020132600A1/en not_active Ceased
-
2025
- 2025-03-17 US US19/081,867 patent/US20250263480A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eustace et al. | Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids | |
| JP2019065029A (ja) | 処置方法 | |
| JP2020019781A (ja) | 抗ｉｌ−５抗体を投与するための方法 | |
| JP2016536332A5 (https=) | ||
| CN115768516A (zh) | 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法 | |
| US20240158518A1 (en) | Pharmaceutical composition for treatment or prevention of myasthenia gravis | |
| JP2022514381A5 (https=) | ||
| JP2022512937A5 (https=) | ||
| WO2016167263A1 (ja) | Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| JP2018515493A5 (https=) | ||
| JP7458790B2 (ja) | Ｉｌ－６阻害剤を含有する喘息の治療剤 | |
| BR112020021721A2 (pt) | tratamento da dermatite atópica | |
| JP2024069230A5 (https=) | ||
| JP2025148449A (ja) | クローン病を治療する方法に使用するためのミリキズマブ | |
| JP2024521638A (ja) | 好酸球トラップの阻害 | |
| US20240425573A1 (en) | Methods for treating alzheimer's disease | |
| AU2018274749A1 (en) | Methods for the treatment of chronic pouchitis | |
| Takagi et al. | Cevimeline gargle for the treatment of xerostomia in patients with Sjögren’s syndrome | |
| PT1737490E (pt) | Processos de tratamento da aterosclerose | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| TW202521124A (zh) | 用於治療發炎性腸道疾病之療法 | |
| Geevarghese | Updates in the Treatment of Kawasaki Disease | |
| RU2822135C2 (ru) | Способы лечения хронического резервуарного илеита | |
| Chen et al. | Analysis of the Clinical Efficacy of Infliximab in the Treatment of Steroid-Refractory Ulcerative Colitis in Children | |
| CN120285174A (zh) | 抗vegf抗体与parp抑制剂联合用于治疗肿瘤 |